We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Senior Pharma Executive Joins LAB International's Pharma Team
News

Senior Pharma Executive Joins LAB International's Pharma Team

Senior Pharma Executive Joins LAB International's Pharma Team
News

Senior Pharma Executive Joins LAB International's Pharma Team

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Senior Pharma Executive Joins LAB International's Pharma Team "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

LAB International Inc. has announced the appointment of Dr. Antti Jekunen to LAB Pharma's senior management team as Senior Vice-President, Clinical and Regulatory Affairs.

Prior to joining LAB International, Dr. Jekunen served as Director, clinical oncology, drug design and development at Brystol-Myers Squibb Pharmaceutical USA, Senior Director in clinical drug development at Ilex Oncology and as Medical Director at Aventis Pharma Finland.

Dr Jekunen brings 15 years of academic and pharmaceutical industry experience of drug development to LAB.

He has been directly responsible for the development and implementation of the clinical and regulatory strategies of several of Rhône-Poulenc Rorer, Aventis and BMS drugs both in Europe and in the US.

"We are very pleased to have Dr. Jekunen join the LAB Pharma executive team. Dr Jekunen brings to LAB a vast and in depth international clinical drug design and development experience acquired at major pharmaceutical companies," said Dr. Halvor Jaeger, Chief Executive Officer of LAB International.

"He will play a key role in our product development programs and regulatory processes as more of our drugs advance into late stage clinical stages."

Advertisement